Investigational drug · Phase 3
FTC
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Infection, Human Immunodeficiency Virus.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
790
Any phase or sponsor naming "FTC"
First trial start
2024
Aug 28, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FTC", any sponsor or status.
Conditions studied
As listed on its trial records.
- Infection, Human Immunodeficiency Virus
Approved drugs for the same conditions: Infectious disease and vaccines · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "FTC" as an intervention, largest first.
- Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV IncidencePivotal-lookingCompleted
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
NCT01509508 · 28,153 participants · Start Mar 2012 · Primary completion Jun 2016
Drug: Immediate ARV treatment initiation with TDF/FTC/EFV · For: HIV Infection
Sites: Hlabisa, South Africa
University of WashingtonAcademic, hospital or other
NCT04666792 · 25,457 participants · Start Mar 1, 2021 · Primary completion Dec 31, 2024
Drug: PrEP · For: HIV Infections; Contraception; STI
Sites: Kisumu, Kenya
- Evaluation of PrEP-30: a Demonstration Project of Pre-exposure Prophylaxis for MSM and Other High-risk Group Clients at the Thai Red Cross Anonymous ClinicEnrolling by invitation
Thai Red Cross AIDS Research CentreAcademic, hospital or other
NCT02437981 · 20,000 participants (planned) · Start Dec 2014 · Primary completion Dec 2024
Drug: PrEP · For: HIV Prevention
Sites: Bangkok, Thailand
- Expanded PrEP Implementation in Communities in NSWPivotal-lookingCompleted
Kirby InstituteGovernment (non-federal)
NCT02870790 · 9,733 participants · Start Mar 2016 · Primary completion Mar 2019
Drug: TDF/FTC · For: HIV; STI
Sites: Canberra, Australia; Albury, Australia; Alexandria, Australia · 31 sites in all
Gilead SciencesGilead Sciences (GILD)
NCT02842086 · 5,399 participants · Start Sep 2, 2016 · Primary completion Jan 31, 2019
Drug: F/TAF; F/TDF and 2 more · For: Pre-Exposure Prophylaxis of HIV-1 Infection
Sites: Beverly Hills, California; Los Angeles, California; Newport Beach, California · 93 sites in all
- Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV InfectionPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT04994509 · 5,368 participants · Start Aug 30, 2021 · Primary completion May 27, 2024
Drug: Oral Lenacapavir (LEN); Subcutaneous (SC) Lenacapavir (LEN) and 6 more · For: Pre-Exposure Prophylaxis of HIV Infection
Sites: Brits, South Africa; Cape Town, South Africa; Durban, South Africa · 28 sites in all
- Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in WomenPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00705679 · 5,029 participants · Start Aug 2009 · Primary completion Aug 2012
Drug: Emtricitabine/tenofovir disoproxil fumarate; Emtricitabine/tenofovir disoproxil fumarate placebo and 4 more · For: HIV Infections
Sites: Johannesburg, South Africa; Asherville, South Africa; Chatsworth, South Africa · 15 sites in all
- The Partners Scale-Up ProjectCompleted
University of WashingtonAcademic, hospital or other
NCT03052010 · 4,898 participants · Start Feb 6, 2017 · Primary completion Dec 15, 2020
Drug: PrEP; ART · For: HIV-1-infection
Sites: Kisumu, Kenya; Thika, Kenya
- Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant CouplesPivotal-lookingCompleted
University of WashingtonAcademic, hospital or other
NCT00557245 · 4,758 participants · Start May 2008 · Primary completion Oct 2013
Drug: Tenofovir Disoproxil Fumarate (TDF); Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and 1 more · For: HIV-1 Infections; HIV Infections
Sites: Eldoret, Kenya; Kisumu, Kenya; Nairobi, Kenya · 9 sites in all
- A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07071623 · 4,580 participants (planned) · Start Nov 10, 2025 · Primary completion Oct 18, 2027
Drug: MK-8527; Emtricitabine/tenofovir disoproxil (FTC/TDF) and 2 more · For: Human Immunodeficiency Virus (HIV); HIV Pre-Exposure Prophylaxis
Sites: Homabay County, Kenya; Thika, Kenya; Nairobi, Kenya · 30 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Evaluation of dried blood spots relative to peripheral blood mononuclear cells for intracellular tenofovir-diphosphate and emtricitabine-triphosphate assessment using liquid chromatography-tandem mass spectrometry.
Lin YT, Sun HY, Cheng CN, et al. · J Pharm Biomed Anal 2027
- Assessment of Carotid Doppler Parameters to Evaluate Volume Status: A Prospective Observational Study.
Farhat H, Abou Dagher G, Zaatari T, et al. · J Am Coll Emerg Physicians Open 2026
- The Micro-battlefield under climate change: the domino effect of freeze-thaw cycles on Tributyl phosphate accumulation in grains via nutritional, metabolomic, and microbial profiling.
Hu J, Xing N, Bao G, et al. · Food Res Int 2026
- Health Care Merger Enforcement in the 2020s: Policy Changes and Enforcement Continuity.
Capps C, Karakas L, Wohlleben M · Med Care Res Rev 2026
- Conventional sonographic phenotype of thyroid oncocytic neoplasms: a pathology-confirmed comparative study.
Li C, Zhu T, Zheng X, et al. · J Ultrasound 2026
- Maternal and pregnancy outcomes in women offered daily oral preexposure prophylaxis during pregnancy and postpartum.
Chi BH, Kacanek D, Brown E, et al. · AIDS 2026
Also in development for Infection, Human Immunodeficiency Virus
- ACC017Phase 33 trials
Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Infection, Human Immunodeficiency Virus
- 2 NRTIsPhase 32 trials
Merck & Co. · Human Immunodeficiency Virus (HIV) Infection, Infection, Human Immunodeficiency Virus, HIV Infections
- DTGPhase 32 trials
Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Infection, Human Immunodeficiency Virus, HIV Infections
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.